Spero Therapeutics
SPRO
54 hedge funds and large institutions have $17.2M invested in Spero Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.41% less ownership
Funds ownership: 27.32% → 26.91% (-0.41%)
4% less funds holding
Funds holding: 56 → 54 (-2)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
18% less capital invested
Capital invested by funds: $20.8M → $17.2M (-$3.66M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $73K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$990K |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$139K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$136K |
| 4 |
Squarepoint
New York
|
+$71.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$848K |
| 2 |
Millennium Management
New York
|
-$352K |
| 3 |
Two Sigma Investments
New York
|
-$93.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$80K |
| 5 |
AIC
AWM Investment Company
New York
|
-$69.3K |
SPRO Hedge Fund Activity: Q3 2023 in Review
54 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2023, worth a combined $17.2M — down 18% from $20.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SPRO and 5 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was Anson Funds Management, adding an estimated $990K. The largest seller was Rock Springs Capital Management, cutting an estimated $848K.
- 54 institutional investors held Spero Therapeutics (SPRO) as of Q3 2023, down from 56 in Q2 2023.
- Funds reported $17.2M of Spero Therapeutics stock for Q3 2023, down 18% quarter-over-quarter.
- 5 funds opened new Spero Therapeutics positions in Q3 2023 and 7 closed out, a net change of -2 holders.
- The largest Spero Therapeutics buyer in Q3 2023 was Anson Funds Management, an estimated $990K added.
- The largest Spero Therapeutics seller in Q3 2023 was Rock Springs Capital Management, an estimated $848K sold.
Based on aggregated 13F filings for Q3 2023.